EZR and osteosarcoma: High expression of ezrin is linked to poor survival in many cancers, including carcinomas of the breast [67,68], esophagus [69], tongue [70], lung (non-small-cell lung cancer) [71], stomach [72], endometrium [73], and osteosarcoma [74], rhabdomyosarcoma [75], soft tissue sarcomas [76] and melanomas [77], and brain astrocytic tumors [78] except for bladder tumors.